GLP-1s and Inflammatory Bowel Disease

If you have Crohn’s disease or ulcerative colitis, the obvious worry about a drug that deliberately slows the gut is whether it will stir up your gut. The pivotal trials cannot tell you, because people with IBD were excluded from them.^[1] What exists instead is a body of retrospective evidence assembled afterwards, and it is worth knowing both what it says and how much weight it can carry.

What the review found

A 2026 systematic review searched the literature to September 2025 and found 14 studies of GLP-1 drugs in adults with IBD. Ten reported significant reductions in body weight, BMI or percentage weight loss. Four showed improvements in metabolic markers, including lower HbA1c and more favorable lipids.^[1]

On the question that actually worries people: across multiple datasets, GLP-1 use was not associated with increased IBD exacerbations.^[1] That is the headline, and it is genuinely reassuring as far as it goes.

Why the question is reasonable in the first place

It is not a vague worry. These drugs delay gastric emptying and slow transit, and their commonest adverse effects — nausea, diarrhea, abdominal pain, constipation — are the same symptoms that IBD produces and that patients and clinicians use to judge whether disease is active.

That overlap is a practical problem separate from any question of harm. New abdominal pain and altered stool on a GLP-1 could be the drug settling in or a flare beginning, and telling those apart is genuinely difficult. Our side-effect timeline covers what the ordinary course looks like, which is the baseline you would be comparing against.

The drug’s side effects and the disease’s symptoms are the same list. That is a diagnostic problem even when nothing is going wrong.

The case for treating it anyway

The review begins from a point worth restating: obesity and metabolic disease are increasingly common in people with IBD, and they influence disease activity and how well treatment works.^[1] This is not a population where excess weight is cosmetic.

So the choice is not between a risk and safety — it is between two managed risks, in a person who often has fewer good options than average. That is a decision for a gastroenterologist who knows your disease history, not one to make from a website, and it is the kind of case where the specialist’s judgment is doing most of the work.

What would change the picture

• A randomized trial that includes people with IBD. The single thing that would convert this from consistent-with-safety to established.
• Prospective data with disease activity scored properly, rather than exacerbations inferred from records where a flare and a side effect can look identical.
• Separate answers for Crohn’s and colitis. They behave differently, and the current evidence largely does not distinguish them.
• Data on people with surgical history or strictures, where slowed transit is a more specific concern than it is in inflammatory disease generally.